A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of MEDI9929 in Adult Subjects with Inadequately Controlled, Severe Asthma

Trial Profile

A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of MEDI9929 in Adult Subjects with Inadequately Controlled, Severe Asthma

Completed
Phase of Trial: Phase II

Latest Information Update: 23 May 2018

At a glance

  • Drugs Tezepelumab (Primary)
  • Indications Asthma
  • Focus Therapeutic Use
  • Acronyms PATHWAY
  • Sponsors Amgen; MedImmune
  • Most Recent Events

    • 23 May 2018 Results assessing Improvements in Asthma-Related Quality of Life, presented at the 114th International Conference of the American Thoracic Society
    • 05 Mar 2018 Results evaluating the effect of tezepelumab on asthma control in patients with severe, uncontrolled asthma presented at the 2018 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
    • 13 Sep 2017 Planned locations also included Poland.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top